; and (ii) the details that need to be included in such disclosures. (b) Prohibited acts with respect to drugs and active pharmaceutical ingredients Section 301 of the Federal Food, Drug, and Cosmetic Act ( 21 U.S.C. 331 ), as amended by section 2(b), is further amended by adding at the end the following: (ggg) The failure of a manufacturer of a drug described in section 506C(a) or an active pharmaceutical ingredient of such a drug, without a reasonable basis as determined by the Secretary, to notify the Secretary of a permanent discontinuance or an interruption, and the reasons for such discontinuance or interruption, as required by section 506C. . (c) Applicability The amendments made by subsections (a) and (b) apply beginning on the date that is 180 days after the date of enactment of this Act.